News >

Mesothelin-Targeted CAR T Cells Show Early Promise in Solid Tumors

Caroline Seymour
Published: Friday, Apr 12, 2019

Prasad S. Adusumilli, MD
Prasad S. Adusumilli, MD
The antitumor activity and tolerability with mesothelin-targeted CAR T-cell therapy in malignant pleural disease from mesothelioma has generated optimism for the approach in solid tumors, according to Prasad S. Adusumilli, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication